Rezafungin, marketed under the brand name Rezzayo, was approved by the FDA on March 22, 2023, for the treatment of candidemia and invasive candidiasis in adult patients with limited or no alternative treatment options. This approval was based on limited clinical safety and efficacy data.
Rezafungin is administered as an intravenous infusion, usually once per week. The standard dosing regimen involves an initial loading dose of 400 mg followed by a maintenance dose of 200 mg once a week. Each infusion is given slowly over approximately one hour.
Common side effects of rezafungin may include:
Some side effects may occur during the injection, such as dizziness, nausea, light-headedness, itching, sweating, headache, chest tightness, back pain, trouble breathing, or swelling in the face.
Serious side effects requiring immediate medical attention include:
Before starting rezafungin, it is important to inform your doctor if you have:
It is not known if rezafungin will harm an unborn baby, so pregnant women should consult their doctor. Breastfeeding women should also seek medical advice before using this medication.
Rezafungin can interact with other medications, including prescription and over-the-counter medicines, vitamins, and herbal products. It is crucial to inform your healthcare provider about all the medications you are currently taking to avoid potential interactions.
Rezafungin should be stored as per the instructions provided with the medication. Your pharmacist can provide detailed storage information.
Rezafungin offers a promising treatment option for adults with serious candida infections, especially those with limited alternatives. Always follow your healthcare provider's instructions and report any side effects or concerns promptly.
In the Synapse database, you can stay updated on the latest research and development advances of all drugs. This service is accessible anytime and anywhere, with updates available daily or weekly. Use the "Set Alert" function to stay informed. Click on the image below to embark on a brand new journey of drug discovery!